drugset / Trial / NCT06848465
LDRT Combined With Immunochemotherapy for Colorectal Cancer With Liver Metastasis
Phase 1
Recruiting
9 enrolled
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
NaSingle-groupOpen-labelTreatment
Summary
In recent years, growing evidences have demonstrated promising synergistic antitumor effects of radiotherapy combined with immunotherapy. More over, LDRT may enhance the antitumor effect of immunotherapy by altering the tumor immune microenvironment (TIME) and adjusting the immune response. In this study, we will explore the safety and feasibility of LDRT and immunochemotherapy in liver metastatic colorectal cancer. 9-18 participants will be enrolled in this study. All will take part at Daping Hospital, Army Medical University.
Timeline
- Start
- 2025-02-28
- Primary completion
- 2026-08-30
- Completion
- 2027-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | — |
| Subject | Oxaliplatin | Small molecule | 130 mg/m2 | Intravenous |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | Intravenous |